BUSCADOR RECOLECTA

Dades de l'article publicat a la revista Food Chemistry, Volume 307, 1 March 2020, 125556. El podeu consultar a http://hdl.handle.net/2445/143358, Data base containing SPME-GC-MS raw analytical data obtained and used by Quintanilla-Casas et al. (Food Chemistry, 2020, 125556). Data correspond to 82 authentic and traceable olive oil samples, declared as EVOO by the suppliers obtained in the framework of OLEUM project (EC H2020 Programme 2014–2020) from seven different EU and non-EU countries: Croatia (n=11); Slovenia (SVN) (n=8); Spain (ESP) (n=17); Italy (ITA) (n=15); Greece (GRC) (n=6); Morocco (MAR) (n=15) and Turkey (TUR) (n=10). With the aim of reflecting the real production scenario, EVOO samples in this prospective study were obtained under usual production practices for commercial purposes, and thus consisted of both monovarietal oils as well as market blends of olive cultivars typical of each geographical origin. Briefly, data correspond to SPME-GC-MS scan intensities of the specific sesquiterpene hydrocarbon (SH) ions (m/z 93, 107, 119, 135, 157, 159, 161, 189 and 204) obtained from the Total Ion Current (TIC) between the 18th to the 30th minute. Thus, 2467 scans were obtained for each m/z ion implying 22203 variables per sample., SPME-GC-MS data have been obtained by researchers in the OLEUM project This work was developed in the context of the project OLEUM “Advanced solutions for assuring authenticity and quality of olive oil at global scale”, funded by the European Commission within the Horizon 2020 Program (2014–2020, grant agreement no. 635690). The information and views set out in this article are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. The study was also supported by the Ministerio de Ciencia, Innovación y Universidades (MICINN) from Spain through the Juan de la Cierva and Ramon y Cajal programs (JCI-2012_13412 and RYC-2017-23601), and by the Ministerio de Educación, Cultura y Deporte (MECD) from Spain through the FPU pre-doctoral program (FPU16/01744).

Study of immune correlates against malaria after vaccination with RTS,S/ASO1E: a comphrensive immunological arm of a Phase III double-blind, randomize, controlled multi-centre trial (MAL067)., Dades primàries associades a l'article publicat a NPJ Vaccines, vol. 5 [https://doi.org/10.1038/s41541-020-0192-7], The RTS,S/AS01E vaccine has shown consistent but partial vaccine efficacy in a pediatric phase 3 26 clinical trial using a 3-dose immunization schedule. A fourth dose 18 months after the primary 27 vaccination was shown to restore the waning efficacy. However, only total IgG against the 28 immunodominant malaria vaccine epitope has been analyzed following the booster. To better 29 characterize the magnitude, nature and longevity of the immune response to the booster, we 30 measured levels of total IgM, IgG and IgG1-4 subclasses against three constructs of the 31 circumsporozoite protein (CSP) and the hepatitis B surface antigen (HBsAg, also present in RTS,S) 32 by quantitative suspension array technology in 50 subjects in the phase 3 trial in Manhiça, 33 Mozambique. To explore the impact of vaccination on naturally acquired immune responses, we 34 measured antibodies to P. falciparum antigens not included in RTS,S. We found increased IgG, 35 IgG1, IgG3 and IgG4, but not IgG2 nor IgM, levels against vaccine antigens one month after the 4th 36 dose. Overall, antibody responses to the booster dose were lower than the initial peak 37 response to primary immunization and children had higher IgG and IgG1 levels than infants. 38 Higher anti-Rh5 IgG and IgG1-4 levels were detected after the booster dose, suggesting that RTS,S 39 partial protection could increase some blood stage antibody responses. Our work shows that the 40 response to the RTS,S/AS01E booster dose is different from the primary vaccine immune 41 response and highlights the dynamic changes in subclass antibody patterns upon the vaccine 42 booster and with acquisition of adaptive immunity to malaria.